Edition:
India

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

187.63USD
1:03am IST
Change (% chg)

$-4.26 (-2.22%)
Prev Close
$191.89
Open
$190.96
Day's High
$192.83
Day's Low
$187.28
Volume
775,889
Avg. Vol
1,333,452
52-wk High
$210.18
52-wk Low
$163.31

Chart for

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.40
Market Cap(Mil.): $135,588.20
Shares Outstanding(Mil.): 729.67
Dividend: 1.15
Yield (%): 2.48

Financials

  AMGN.OQ Industry Sector
P/E (TTM): 16.90 29.30 32.54
EPS (TTM): 11.00 -- --
ROI: 11.98 14.23 13.82
ROE: 26.43 15.46 15.25

Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug

Biotech company Amgen Inc said on Monday a U.S. jury confirmed the validity of patents on its cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA.

26 Feb 2019

Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug

Biotech company Amgen Inc said on Monday a U.S. jury confirmed the validity of patents on its cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA.

26 Feb 2019

UPDATE 2-Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug

Feb 25 Biotech company Amgen Inc said on Monday a U.S. jury confirmed the validity of patents on its cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA.

26 Feb 2019

CORRECTED-UPDATE 1-Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug -report

Feb 25 A U.S. jury said on Monday that patents owned by Amgen Inc on its cholesterol drug Repatha are valid, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA, Bloomberg reported.

26 Feb 2019

CORRECTED-Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug

Feb 25 A U.S. jury on Monday said patents owned by Amgen Inc on its cholesterol drug Repatha are valid, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA, Bloomberg reported.

26 Feb 2019

Sanofi and Regeneron cut list price of cholesterol drug by 60 percent

NEW YORK Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug.

11 Feb 2019

Sanofi and Regeneron cut list price of cholesterol drug by 60 pct

NEW YORK, Feb 11 Sanofi SA and Regeneron Pharmaceuticals Inc said on Monday that they will slash the U.S. list price of their potent but expensive cholesterol fighter Praluent by 60 percent, as the drugmakers follow a similar move by rival Amgen Inc in hopes of increasing use of the drug.

11 Feb 2019

Amgen 2019 forecast falls short of expectations, shares dip

Amgen Inc on Tuesday reported fourth-quarter profit that easily surpassed expectations as sales rose and tax expense fell, but competition for its older medicines is growing and the drugmaker forecast 2019 earnings below Wall Street estimates.

30 Jan 2019

UPDATE 2-Amgen 2019 forecast falls short of expectations, shares dip

Jan 29 Amgen Inc on Tuesday reported fourth-quarter profit that easily surpassed expectations as sales rose and tax expense fell, but competition for its older medicines is growing and the drugmaker forecast 2019 earnings below Wall Street estimates.

30 Jan 2019

Amgen quarterly profit tops Street view, 2019 forecast falls short

Jan 29 Amgen Inc on Tuesday reported higher-than-expected fourth-quarter profit as sales rose and tax expense fell, but competition for older medicines is growing and the drugmaker forecast 2019 earnings below Wall Street estimates.

30 Jan 2019

Earnings vs. Estimates